Strategy Consultants to the Life Sciences Industry

White papers represent the synthesis of ClearView’s perspective on key areas of interest within the broader life sciences industry.

Launching a new therapy is a complex endeavor. There are no second chances. A biotech company must be aware...

Photo of cover page

Enhancing and Widening Your Asset’s Potential Successful R&D strategies aren’t always able to avoid every wrong turn, but they...

Trends in Development, Discovery, and Disruptive Technologies This presentation, initially shared as Super Session talk at BIO 2018 in...

Establishing market access and reimbursement for new pharmaceuticals is perhaps harder today than at any point in the industry’s...

rare disease, pharmaceuticals, drug prices, market access, Orkambi, VIMIZIM

The historical access environment for orphan drugs was based on a few critical factors, namely that these products addressed...

Digital technologies are proliferating at unprecedented rates and are poised to transform the healthcare industry. Medtech companies are uniquely...

Patient advocacy groups (PAGs) excel in bringing together multiple stakeholders – KOLs, physicians, caregivers, policy makers, and patients – throughout...

Establishing Trust For any emerging biotech company with a novel platform technology, establishing trust in that platform is essential...

For an emerging biotech, a traditional commercial opportunity assessment is an essential part of the partnering process for a...

Determining Your Commercialization Plan Deciding whether to partner an important late-stage asset or commercialize it independently is a biotech...

Translating Science and Technology into Commercial Opportunity In the first white paper in our series “Growing Up Biotech”, we...

A Key Piece of the Puzzle Patient advocacy groups play an increasingly important role in the drug development and...

Dramatic growth in the immuno-oncology field suggests a paradigm shift across oncology in the coming years. This evolution will...

Key Trade-offs for Drug Developers Orphan drug development is attractive to drug developers for many compelling reasons: tax advantages,...

Strategies to Optimize Performance in the Era of Precision Medicine Informed drug development in an era of “precision medicine”...

Implications and Strategic Business Considerations The breakthrough therapy designation has generated substantial interest since its creation one year ago,...